Yissum Licenses Nano Drug-Delivery Tech to Italian Corporate Venture Firm Z-Cube for Pain Rxs | GenomeWeb

Yissum, the technology-transfer company of the Hebrew University of Jerusalem, and Z-Cube, the corporate venture arm of Italian pharmaceutical firm Zambon, said this week that they have signed an agreement to develop and commercialize a nanotechnology drug-delivery system for treating pain.

The technology is the latest to emerge from the laboratory of Hebrew University researcher Elka Touitou, whose drug-delivery research has previously served as the basis for two startup companies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.